Cécile Acquaviva

Dr. Cécile Acquaviva

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
MSManuel Schiff
Manuel Schiff
AVAlice Veauville-Merllié
Alice Veauville-Merllié
CSChen Hsien Su
Chen Hsien Su
ATAlexander Tzagoloff
Alexander Tzagoloff
MRMalgorzata Rak
Malgorzata Rak
CACécile Acquaviva
Cécile Acquaviva
A patient with late-onset exercise intolerance had haploinsufficiency of SLC25A32, which encodes the human mitochondrial flavin adenine dinucleotide transporter. The patient's symptoms were highly responsive to oral supplementation with riboflavin.

23 September 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MNMathilde Nizon
Mathilde Nizon
COChris Ottolenghi
Chris Ottolenghi
VVVassili Valayannopoulos
Vassili Valayannopoulos
JAJean-Baptiste Arnoux
Jean-Baptiste Arnoux
VBValérie Barbier
Valérie Barbier
PLPascale de Lonlay
Pascale de Lonlay
Background: Classical organic acidurias including methylmalonic aciduria (MMA), propionic aciduria (PA) and isovaleric aciduria (IVA) are severe inborn errors of the catabolism of branched-chain amino acids and odd-numbered chain fatty acids, presenting with severe complications. Methods: This study investigated the long-term outcome of 80 patients with classical organic aciduria (38 with MMA, 24 with PA and 18 with IVA) by integrating clinical, radiological, biochemical and genetic data. Results: Patients were followed-up for a mean of 14 years [age 3.3-46.3 years]. PA included a greater number of patients with abnormal neurological examination (37% in PA, 24% in MMA and 0% in IVA), lower psychometric scores (abnormal evaluation at age 3 years in 61% of patients with PA versus 26% in MMA and 18% in IVA) and more frequent basal ganglia lesions (56% of patients versus 36% in MMA and 17% in IVA). All patients with IVA presented a normal neurological examination and only 1/3 presented cognitive troubles. Prognosis for MMA was intermediate. Biochemical metabolite analysis excluding acute decompensations revealed significant progressive increases of glycine, alanine and glutamine particularly in PA and possibly in MMA but no correlation with neurological outcome. A significant increase of plasma methylmalonic acid was found in MMA patients with intellectual deficiency (mean level of 199 μmol/L versus 70 μmol/L, p < 0.05), with an estimated significant probability of severe outcome for average levels between birth and age 6 years above 167 μmol/L. Urinary 3-hydroxypropionate (3-HP) levels were significantly higher in PA patients with intellectual deficiency (mean level of 68.9 μmol/mmol of creatinine versus 34.6 μmol/mmol of creatinine, p < 0.01), with an estimated significant probability of severe outcome for average levels between birth and age 6 years above 55 μmol/mmol. As for molecular analysis, prognosis of MMA patients with mutations involving the MMAA gene was better compared to patients with mutations involving the MUT gene. Conclusion: Propionic aciduria had the most severe neurological prognosis. Our radiological and biochemical data are consistent with a mitochondrial toxicity mechanism. Follow-up plasma MMA and urinary 3-HP levels may have prognostic significance calling for greater efforts to optimize long-term management in these patients.

1 December 2016 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
Frederic CapelFrederic Capel
Frederic Capel
NCNaoufel Cheraiti
Naoufel Cheraiti
CACécile Acquaviva
Cécile Acquaviva
CHCarole Henique
Carole Henique
Justine Bertrand-MichelJustine Bertrand-Michel
Justine Bertrand-Michel
BMBéatrice Morio
Béatrice Morio

29 May 2020 in Urolithiasis
Verified
Journal Article
Open access
PDF file
FSFelicity Stokes
Felicity Stokes
CACécile Acquaviva
Cécile Acquaviva
BHBernd Hoppe
Bernd Hoppe
JLJohn C. Lieske
John C. Lieske
ELElisabeth Lindner
Elisabeth Lindner
GRGill Rumsby
Gill Rumsby
Measurement of oxalate in the blood is essential for monitoring primary hyperoxaluria patients with progressive renal impairment and on dialysis prior to transplantation. As no external quality assurance scheme is available for this analyte, we conducted a sample exchange scheme between six laboratories specifically involved with the investigation of primary hyperoxaluria to compare results. The methodologies compared were gas chromatography/mass spectrometry (GCMS), ion chromatography with mass spectrometry (ICMS), and enzymatic methods using oxalate oxidase and spectrophotometry. Although individual laboratories performed well in terms of reproducibility and linearity, there was poor agreement (absolute values) between centres as illustrated by a longer-term comparison of patient results from two of the participating laboratories. This situation was only partly related to differences in calibration and mainly reflected the lower recoveries seen with the ultrafiltration of samples. These findings lead us to conclude that longitudinal monitoring of primary hyperoxaluria patients with deteriorating kidney function should be performed by a single consistent laboratory and the methodology used should always be defined. In addition, plasma oxalate concentrations reported in registry studies and those associated with the risk of systemic oxalosis in published studies need to be interpreted in light of the methodology used. A reference method and external quality assurance scheme for plasma oxalate analysis would be beneficial.

Verified
Journal Article
Open access
PDF file
IMIrma Machuca-Gayet
Irma Machuca-Gayet
TQThomas Quinaux
Thomas Quinaux
ABAurélia Bertholet-Thomas
Aurélia Bertholet-Thomas
SGSégolène Gaillard
Ségolène Gaillard
DCDébora Claramunt-Taberner
Débora Claramunt-Taberner
JBJustine Bacchetta
Justine Bacchetta
Patients with chronic kidney disease (CKD) display significant mineral and bone disorders (CKD-MBD) that induce significant cardiovascular, growth and bone comorbidities. Nephropathic cystinosis is an inherited metabolic disorder caused by the lysosomal accumulation of cystine due to mutations in the CTNS gene encoding cystinosin, and leads to end-stage renal disease within the second decade. The cornerstone of management relies on cysteamine therapy to decrease lysosomal cystine accumulation in target organs. However, despite cysteamine therapy, patients display severe bone symptoms, and the concept of “cystinosis metabolic bone disease” is currently emerging. Even though its exact pathophysiology remains unclear, at least five distinct but complementary entities can explain bone impairment in addition to CKD-MBD: long-term consequences of renal Fanconi syndrome, malnutrition and copper deficiency, hormonal disturbances, myopathy, and intrinsic/iatrogenic bone defects. Direct effects of both CTNS mutation and cysteamine on osteoblasts and osteoclasts are described. Thus, the main objective of this manuscript is not only to provide a clinical update on bone disease in cystinosis, but also to summarize the current experimental evidence demonstrating a functional impairment of bone cells in this disease and to discuss new working hypotheses that deserve future research in the field.

5 January 2023 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
CVChristine Vianey-Saban
Christine Vianey-Saban
AFAlain Fouilhoux
Alain Fouilhoux
JVJerry Vockley
Jerry Vockley
CACécile Acquaviva
Cécile Acquaviva
NGNathalie Guffon
Nathalie Guffon